Research prospects with benfluorex

Journal of Diabetes and its Complications

Volumn 10, Issue 5, 1996, Pages 246-254

  Ravel, Denis ^a   Laudignon, Nicole ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BENFLUOREX; INSULIN; INSULIN RECEPTOR;

ADRENAL GLAND; DIABETES MELLITUS; DRUG MECHANISM; DRUG POTENTIATION; GLUCONEOGENESIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BILAYER; NEUROENDOCRINE SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE;

EID: 0030578873     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(96)00045-1     Document Type: Article

References (56)

1. 1. Riccio A, Vigili de Kreutzenberg S, Dorella M, Da Tos V, De Biasi L, Marescotti MC, Tiengo A, Del Prato S: Mechanism(s) of the blood glucose lowering action of benfluorex. Diabetes Metab Rev 9 (suppl 1):19S, 1993.
2. 2. Bianchi R, Bongers V, Bravenboer B, Erkelens DW: Benfluorex decreases insulin resistance and improves lipid profiles in obese type II diabetic patients. Diabetes Metab Rev 9 (suppl 1):29S, 1993.
3. 3. De Feo P, Lavielle R, De Gregoris P, Bolli GB: Anti-hyperglycaemic mechanisms of Benfluorex in type II Diabetes Mellitus. Diabetes Metab Rev 9 (Suppl 1):35S, 1993.
4. 4. Nestler JE, Beer NA, Jakubowicz DJ, Colombo C, Beer RM: Effect of insulin reduction with benfluorex on serum DHEA, DHEA sulfate, and blood pressure in hypertensive middle-aged and elderly men. J Clin Endocrinol Metab 80:700-706, 1995.
5. 5. Geelen MJH, Vaartjes WJ: Recherche du mécanisme d'action d'une nouvelle substance, le benfluorex, sur le métabolisme intermédiaire; Étude expérimentale sur hépatocytes isolés de rat. Pharmatherapeutica 1:466-476, 1977.
6. 6. Beynen AC, Van der Molen AJ, Geelen MJH: Inhibition of cholesterol synthesis in isolated hepatocytes by salicylate. Pharm Weekbl [Sci] 3:116, 1981.
7. 7. Sommariva D, Blasi F, Cosentini R, Berruto M: Effects of benfluorex on sterol biosynthesis in incubated human blood mononuclear cells. Drugs Exp Clin Res XII:923-927, 1986.
8. 8. Orsière T, Chauvet M, Dell'Amico M, Lafont H, Bourdeaux M: In vitro influence of benfluorex and its main metabolites on rat liver microsomal membrane properties. Chemico-Biological Interactions 97:297-306, 1995.
9. 9. Mazière JC, Mazière C, Auclair M, Mora L, Arnaud O: The liver metabolite S-422 of the hypolipidaemic drug benfluorex decreases cholesterol esterification in fibroblasts and monocyte-like cells. Eur J Clin Pharmacol 41: 339-344, 1991.
10. 10. Brindley DN: Phenylethylamines and their effects on the synthesis of fatty acids, triacylglycerols and phospholipids, in: Curtis-Prior PB, (ed), Obesity Amsterdam, Elsevier, 1982, pp. 285-308.
11. 11. Melin B, Blivet MJ, Caron M, Cherqui G, Arnaud O, Picard J, Capeau J: Effect of benfluorex on glucose and lipid metabolism and insulin action in cultured rat hepatocytes. Diabetologia 34:488, 1991.
12. 12. Geelen MJH: Mechanisms responsible for the inhibitory effects of benfluorex on hepatic intermediary metabolism. Biochem Pharmacol 32:1765-1772, 1983.
13. 13. Slusarczyk H, Turner P: Studies on benfluorex and its metabolites on glucose uptake into rat hemidiaphragm. Br J Pharmacol 73:272P, 1981.
14. 14. Ailhaud G, Verrando P, Negrel R: Long-term effects of benfluorex on glucose utilization in the preadipocyte ob 17 cell line. Diabetologia 21:241, 1981.
15. 15. Serradas P, Blondel O, Bailbé D, Portha B: Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. Diabetes 42:564-570, 1993.
16. 16. Yamaguchi N: Sympathoadrenal system in neuroendocrine control of glucose: mechanisms involved in the liver, pancreas, and adrenal gland under hemorrhagic and hypoglycemic stress. Can J Physiol 70:167-206, 1991.
17. 17. Shimazu T, Fukuda A: Increased activities of glycogenolytic enzymes in liver after splanchnic nerve stimulation. Science 150:1607-1608, 1965.
18. 18. Lautt WW: Hepatic nerves: A review of their functions and effects. Can J Physiol Pharmacol 58:105-123, 1980.
19. 19. Edwards AV: The sensitivity of the hepatic glycogenolytic mechanism to stimulation of the splanchnic nerves. J Physiol 220:315-334, 1972.
20. 20. Shimazu T: Neuronal regulation of hepatic glucose metabolism in mammals. Diabetes Metab Rev 3:185-206, 1987.
21. 21. Tielens AGM, Van der Heuvel JM, Schmitz MGJ, Geelen MJH: Effect of chronic benfluorex treatment on the activities of key enzymes of hepatic carbohydrate metabolism in old Sprague-Dawley rats. Biochem Pharmacol 46:1539-1544, 1993.
22. 22. Kaufman LN, Peterson MM, Smith SM: Hypertension and sympathetic hyperactivity induced in rats by high-fat or glucose diets. Am J Physiol 260:E95-E100, 1991.
23. 23. Daly PA, Landsberg L: Hypertension in obesity and NIDDM: Role of insulin and sympathetic nervous system. Diabetes Care 14:240-247, 1991.
24. 24. Young JB, Landsberg L: Stimulation of the sympathetic nervous system during sucrose feeding. Nature 269:615-617, 1977.
25. 25. Schwartz JH, Young JB: Landsberg L: Effect of dietary fat on sympathetic nervous system activity in the rat. J Clin Invest 72:361-370, 1983.
26. 26. Pascoe WS, Smythe GA, Storlien LH: Enhanced responses to stress induced by fat-feeding in rats: Relationship between hypothalamic noradrenaline and blood glucose. Brain Res 550:192-196, 1991.
27. 27. Storlien LH, Oakes ND, Pan DA, Kusunoki M, Jenkins AB: Syndromes of insulin resistance in rat. Diabetes 42: 457-462, 1993.
28. 28. Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm J, Storlien LH: Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40:1397, 1991.
29. 29. Storlien LH, James DE, Burleigh KM, Chisholm DJ, Kraegen EW: Fat feeding causes widespread in vivo insulin resistance, decreased energy expenditure, and obesity in rats. Am J Physiol 251:E576-E583, 1986.
30. 30. Danforth E Jr: Diet and obesity. Am J Clin Nutr 41:1132-1145, 1985.
31. 31. Storlien LH, Oakes ND, Pan DA, Kusunoki M, Jenkins A. Syndromes of insulin resistance in the rat: Inducement by diet and amelioration with benfluorex. Diabetes 42: 457-462, 1993.
32. 32. Barnard RJ, Faria BJ, Menges JE, Martin DA: Effects of a high-fat, sucrose diet on serum insulin and related atherosclerosis risk factors in rats. Atherosclerosis 100:229-236, 1993.
33. 33. I-Shun H, Ho H, Hoffman BB, Reaven GM: Fructose-induced insulin resistance and hypertension in rats. Hypertension 10:512-516, 1987.
34. 34. Brindley DN, Cooling J, Glenny HP, Burditt SL, McKechnie IS: Effects of chronic modification of dietary fat and carbohydrate on the insulin, corticosterone and metabolic responses of rats fed acutely with glucose, fructose or ethanol. Biochem J 200:275-283, 1981.
35. 35. Brindley DN, Akester H, Derrick GP, Irvine CD, Patmore RD, Spencer H, Yule-Smith A, Finnerty C, Saxton J, MacDonald IA, Rolland Y: Effects of chronic administration of benfluorex to rats on the metabolism of corticosterone, glucose, triacylglycerols, glycerol and fatty acid. Biochem Pharmacol 37:695-705, 1988.
36. 123 chez le rat obèse Zucker (fa/fa). La Presse Médicale 21:1336-1339, 1992.
37. 37. Russel JC, Graham SE, Dolphin PJ, Amy RM, Wood GO, Brindley DN: Antiatherogenic effects of long-term benfluorex treatment in male insulin resistant JCR: LA-cp rats. Circulation 1996 (submitted).
38. 38. Marquié G, El Madani T, Khal Layoun S, Hadjiisky P, Ravel D, Bennani N: Effects of the hypolipidemic agent benfluorex on the development of atherosclerosis in diabetic sand rats (Psammomys obesus). Atherosclerosis 221: 314-315, 1994.
39. 39. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement IV JP, Boyd III AE, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, Nelson DA: Cloning of the β cell high-affinity sulphonylurea receptor: A regulator of insulin secretion. Science 268:423-425, 1995.
40. +-channels. Diabetes Clin Pract 28 (suppl):S67-S80, 1995.
41. 41. Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H: Characterization of new oral antidiabetic agent CS-045. Studies in KK and db/db mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988.
42. 42. Kuzuya T, Iwamoto Y, Kosaka K, Takebe K, Yamanouchi T, Kasuga M, Kajinuma H, Akanuma Y, Yoshida S, Shigeta Y, Baba S: A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus. Diabetes Res Clin Pract 11:147-154, 1991.
43. 43. Kosaka K, Kuzuya T, Akanuma Y: Clinical evaluation of a new oral hypoglycaemic agent CS-045 in patients with non-insulin-dependent diabetes mellitus poorly controlled by sulphonylureas. A double-blind, placebo-controlled study (Rinsho Iyaku). J Clin Ther Med 9 (suppl 3): 95-126, 1993.
44. 44. Prange-Hansen A: Effects of troglitazone, a thiazolidinedione, in elderly non-insulin-dependent diabetic patients. Diabetologia 38:A200, 1995.
45. 45. Bailey CJ, Flatt PR. New Antidiabetic Drugs. London, Smith Gordon Nishimura, 1992.
46. 46. Ibrahimi A, Teboul E, Gaillard D, Amri EZ, Ailhaud G, Young P, Cawthorne MA, Grimaldi PA: Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol 46:1070-1076, 1994.
47. 47. Storlien LH, Borkman A, Jenkins AB, Campbell LV: Diet and in vivo insulin action of rats and man. Diabetes Nutr Metab 4:227-240, 1991.
48. 48. Randle PJ, Garland PB, Wales CN, Newsholme A: The glucose fatty-acid cycle, its role in insulin sensitivity and metabolic disturbances of diabetes mellitus. Lancet 1:785-799, 1963.
49. 49. Young JB: Effect of experimental hyperinsulinemia on sympathetic nervous system activity in rat. Life Sci 49: 193-200, 1988.
50. 50. Rowe JW, Young JB, Minaker KL, Stevens AL, Palotta J, Landsberg L: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 30:219-225, 1981.
51. 51. Modan M, Halkin H: Hyperinsulinemia or increased sympathetic drive as links for obesity and hypertension. Diabetes Care 14:470-487, 1991.
52. 52. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ(PPARγ). J Biol Chem 270: 12953-12956, 1995.
53. 53. Brichard SM, Henquin JC: The role of vanadium in the management of diabetes. Tips 16:265-270, 1995.
54. 54. Srivastava AK: Potential use of vanadium compounds in the treatment of diabetes mellitus. Exp Opin Invest Drugs 4:525-536, 1995.
55. 55. Brindley DN, Bowley M: Effects of fenfluramine and related compounds on the synthesis of glycerolipids by rat liver. Postgrad Meet J 51 (suppl 1):91-95, 1975.
56. 56. Bailey CJ, Page T, Day C, Thorburn CC: Acute effect of benfluorex on glucose metabolism. Biochem Pharmacol 44:379-382, 1992.